Four-Year quest for safer nerve disease control

NCT ID NCT06859099

ENROLLING_BY_INVITATION Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study aims to understand the long-term safety and effectiveness of the drug riliprubart for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder. About 300 participants who have already been taking riliprubart in earlier studies can continue treatment for up to 3 years and be followed for safety. The main goal is to see if the drug continues to control the disease and prevent relapses over a longer period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYNEUROPATHY, INFLAMMATORY DEMYELINATING, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alabama Neurology Associates- Site Number : 8400019

    Homewood, Alabama, 35209, United States

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760004

    Ribeirão Preto, São Paulo, 14049-900, Brazil

  • Investigational Site Number : 0320003

    Buenos Aires, 1221, Argentina

  • Investigational Site Number : 1240001

    Gatineau, Quebec, J8Y 1W2, Canada

  • Investigational Site Number : 1240002

    Québec, Quebec, G1E 7G9, Canada

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, 8207257, Chile

  • Investigational Site Number : 1520003

    Lo Barnechea, Reg Metropolitana de Santiago, 7691236, Chile

  • Investigational Site Number : 1560001

    Shanghai, 200040, China

  • Investigational Site Number : 1560002

    Fuzhou, 350001, China

  • Investigational Site Number : 1560003

    Wuhan, 430030, China

  • Investigational Site Number : 1560005

    Beijing, 100053, China

  • Investigational Site Number : 1560006

    Wuhan, 430060, China

  • Investigational Site Number : 1560011

    Chengdu, 610072, China

  • Investigational Site Number : 1560013

    Beijing, 100034, China

  • Investigational Site Number : 2030001

    Prague, 128 08, Czechia

  • Investigational Site Number : 2030004

    Brno, 625 00, Czechia

  • Investigational Site Number : 2080002

    Aarhus, 8200, Denmark

  • Investigational Site Number : 2500001

    Le Kremlin-Bicêtre, 94270, France

  • Investigational Site Number : 2500002

    Marseille, 13885, France

  • Investigational Site Number : 2500004

    Paris, 75651, France

  • Investigational Site Number : 2500005

    Toyama, 939-2716, Japan

  • Investigational Site Number : 2500007

    Bordeaux, 33076, France

  • Investigational Site Number : 2760002

    Göttingen, 37075, Germany

  • Investigational Site Number : 2760004

    Tübingen, 72076, Germany

  • Investigational Site Number : 3800001

    Milan, Milano, 20132, Italy

  • Investigational Site Number : 3800002

    Rome, Roma, 00168, Italy

  • Investigational Site Number : 3800003

    Genoa, Genova, 16132, Italy

  • Investigational Site Number : 3800004

    Rozzano, Milano, 20089, Italy

  • Investigational Site Number : 3800005

    Pavia, 27100, Italy

  • Investigational Site Number : 3800007

    Pisa, 56126, Italy

  • Investigational Site Number : 3920012

    Higashi-Matsuyama, Saitama, 355-0005, Japan

  • Investigational Site Number : 4100003

    Seoul, Seoul-teukbyeolsi, 02841, South Korea

  • Investigational Site Number : 5280001

    Amsterdam, 1105 AZ, Netherlands

  • Investigational Site Number : 6160001

    Lublin, Lublin Voivodeship, 20-954, Poland

  • Investigational Site Number : 6880001

    Belgrade, 11000, Serbia

  • Investigational Site Number : 7240001

    Barcelona, Catalunya [Cataluña], 08041, Spain

  • Investigational Site Number : 7240002

    Barcelona, 08035, Spain

  • Investigational Site Number : 7240003

    Valencia, 46026, Spain

  • Investigational Site Number : 7240004

    Majadahonda, Madrid, 28222, Spain

  • Investigational Site Number : 7520001

    Stockholm, 113 65, Sweden

  • University of Kansas Medical Center- Site Number : 8400010

    Kansas City, Kansas, 66160, United States

Conditions

Explore the condition pages connected to this study.